Endo International plc (ENDP)
(Delayed Data from NSDQ)
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.20 USD
+0.48 (6.22%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.19 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.
Company News For Aug 9, 2018
by Zacks Equity Research
Companies In The News are: KORS,XEC,DDD,ENDP
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.
Implied Volatility Surging for Endo International (ENDP) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Endo International (ENDP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 38.18% and 4.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?
by Zacks Equity Research
During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
What's in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.
Zoetis (ZTS) Gears Up for Q2 Earnings: What's in Store?
by Zacks Equity Research
We expect Zoetis (ZTS) to throw more light on its Abaxis acquisition plans and other pipeline updates during second-quarter 2018 earnings call.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
In the second quarter of 2018, Agenus (AGEN) should focus on its pipeline candidates and provide updates on them as many of its pipeline candidates are under evaluation for various indications.
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
Is a Beat in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.
Is Endo International a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if Endo International (ENDP) stock is a good choice for value-oriented investors right now from multiple angles.
Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER
by Zacks Equity Research
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
BioMarin Begins Pediatric Study on Achondroplasia Candidate
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
Endo International (ENDP) Up 12.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Endo International (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.
Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings
by Ekta Bagri
Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.
Is the Options Market Predicting a Spike in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors need to pay close attention to Endo International (ENDP) stock based on the movements in the options market lately.
Factors Likely to Impact Zillow (ZG) This Earnings Season
by Zacks Equity Research
Zillow (ZG) to benefit from increasing traffic at its mobile apps and websites, strong rental demand and expanding Multiple Listing Services partnerships.
Are Options Traders Betting on a Big Move in Endo International (ENDP) Stock?
by Zacks Equity Research
Investors in Endo International (ENDP) need to pay close attention to the stock based on moves in the options market lately.
What Falling Estimates & Price Mean for Endo International (ENDP)
by Zacks Equity Research
Endo International (ENDP) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.